Skip to main content
Erschienen in: gynäkologie + geburtshilfe 2/2014

01.04.2014 | Zertifizierte Fortbildung

Neoadjuvante Therapieoptionen

Operables Mammakarzinom

verfasst von: PD Dr Cornelia Liedtke, Prof. Dr. Achim Rody, Dr. Kristin Baumann

Erschienen in: gynäkologie + geburtshilfe | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Initial erfolgten neoadjuvante Behandlungen, um lokal fortgeschrittene Primärtumoren operabel zu machen. Heute werden mit den präoperativen Therapien verschiedene Ziele verfolgt. Etwa Patientinnen eine brusterhaltende Operation zu ermöglichen, das kosmetische Ergebnis zu verbessern und das Verhalten des Tumors unter Chemotherapie zu überwachen.
Literatur
1.
Zurück zum Zitat Boughey JC et al. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg. 2006;244(3):464–70.PubMedCentralPubMed Boughey JC et al. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg. 2006;244(3):464–70.PubMedCentralPubMed
2.
Zurück zum Zitat Fisher ER et al: Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer. 2002;95(4):681–95.PubMedCrossRef Fisher ER et al: Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer. 2002;95(4):681–95.PubMedCrossRef
3.
Zurück zum Zitat Kaufmann M et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19(5):1508–16.PubMedCrossRef Kaufmann M et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19(5):1508–16.PubMedCrossRef
4.
Zurück zum Zitat Fisher B. Der Einfluß aktueller Ergebnisse klinischer NSABP Studien auf Paradigmen zur Behandlung und Prävention des primären invasiven Mammakarzinoms. In: Untch M, Sittek H, Bauerfeind I et al. (Hrsg) Diagnostik und Therapie des Mammakarzinoms State of Art. Wien, New York: Zuckscherdt; 2002. S. 480–1. Fisher B. Der Einfluß aktueller Ergebnisse klinischer NSABP Studien auf Paradigmen zur Behandlung und Prävention des primären invasiven Mammakarzinoms. In: Untch M, Sittek H, Bauerfeind I et al. (Hrsg) Diagnostik und Therapie des Mammakarzinoms State of Art. Wien, New York: Zuckscherdt; 2002. S. 480–1.
5.
Zurück zum Zitat von Minckwitz G et al. Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes. J Clin Oncol. 2012;30(15):1796–804CrossRef von Minckwitz G et al. Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes. J Clin Oncol. 2012;30(15):1796–804CrossRef
6.
Zurück zum Zitat Liedtke C et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275–81.PubMedCrossRef Liedtke C et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275–81.PubMedCrossRef
7.
Zurück zum Zitat Cortazar P et al. Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC). Cancer Res. 2012;72(24 Suppl):Abstr. S1–11 Cortazar P et al. Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC). Cancer Res. 2012;72(24 Suppl):Abstr. S1–11
8.
Zurück zum Zitat von Minckwitz G et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst. 2008;100(8):542–51CrossRef von Minckwitz G et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst. 2008;100(8):542–51CrossRef
9.
Zurück zum Zitat von Minckwitz G et al. Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients — Results of the GeparTrio trial. Cancer Res. 2011;71(24 Suppl):Abstr. S3–2. von Minckwitz G et al. Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients — Results of the GeparTrio trial. Cancer Res. 2011;71(24 Suppl):Abstr. S3–2.
10.
Zurück zum Zitat Untch M et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011;29(25):3351–7.PubMedCrossRef Untch M et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011;29(25):3351–7.PubMedCrossRef
11.
Zurück zum Zitat Baselga J et al. Pertuzumab and Trastuzumab: Re-Responses to 2 Biological Agents in Patients with HER2-Positive Breast Cancer Which Had Previously Progressed during Therapy with Each Agent Given Separately: A New Biological and Clinical Observation. Cancer Res. 2009;69(24 Suppl):Abstr. 5114.CrossRef Baselga J et al. Pertuzumab and Trastuzumab: Re-Responses to 2 Biological Agents in Patients with HER2-Positive Breast Cancer Which Had Previously Progressed during Therapy with Each Agent Given Separately: A New Biological and Clinical Observation. Cancer Res. 2009;69(24 Suppl):Abstr. 5114.CrossRef
12.
Zurück zum Zitat Gianni L et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32.PubMedCrossRef Gianni L et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32.PubMedCrossRef
13.
Zurück zum Zitat Schneeweiss A et al. Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: a randomized phase II study (TRYPHAENA). Cancer Res. 2011;71(24 Suppl):Abstr. S5–6. Schneeweiss A et al. Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: a randomized phase II study (TRYPHAENA). Cancer Res. 2011;71(24 Suppl):Abstr. S5–6.
14.
Zurück zum Zitat von Minckwitz G et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012;366(4):299–309.CrossRef von Minckwitz G et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012;366(4):299–309.CrossRef
15.
Zurück zum Zitat Bear HD et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. J Clin Oncol. 2011;29(15 Suppl): LBA1005. Bear HD et al. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40. J Clin Oncol. 2011;29(15 Suppl): LBA1005.
16.
Zurück zum Zitat Mazouni C et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007;25(19):2650–5.PubMedCrossRef Mazouni C et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007;25(19):2650–5.PubMedCrossRef
17.
Zurück zum Zitat von Minckwitz G et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–804.CrossRef von Minckwitz G et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–804.CrossRef
18.
Zurück zum Zitat Symmans WF et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414–22.PubMedCrossRef Symmans WF et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414–22.PubMedCrossRef
19.
Zurück zum Zitat Rody A et al. The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. Breast. 2007;16(3):235–40.PubMedCrossRef Rody A et al. The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. Breast. 2007;16(3):235–40.PubMedCrossRef
20.
Zurück zum Zitat Bidard FC et al. p53 status and efficacy of primary anthracyclines/alkylating agentbased regimen according to breast cancer molecular classes. Ann Oncol. 2008;19(7):1261–5.PubMedCrossRef Bidard FC et al. p53 status and efficacy of primary anthracyclines/alkylating agentbased regimen according to breast cancer molecular classes. Ann Oncol. 2008;19(7):1261–5.PubMedCrossRef
21.
Zurück zum Zitat Fernández-Morales LA et al. Analysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor, progesterone receptor, and HER2 status. Clin Breast Cancer. 2007;7(7):559–64.PubMedCrossRef Fernández-Morales LA et al. Analysis of the pathologic response to primary chemotherapy in patients with locally advanced breast cancer grouped according to estrogen receptor, progesterone receptor, and HER2 status. Clin Breast Cancer. 2007;7(7):559–64.PubMedCrossRef
22.
Zurück zum Zitat Carey LA et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329–34.PubMedCrossRef Carey LA et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329–34.PubMedCrossRef
23.
Zurück zum Zitat Rouzier R et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11(16):5678–85.PubMedCrossRef Rouzier R et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11(16):5678–85.PubMedCrossRef
24.
Zurück zum Zitat Denkert C et al. Ki67 Levels in Pretherapeutic Core Biopsies as Predictive and Prognostic Parameters in the Neoadjuvant GeparTrio Trial. Cancer Res. 2012;72(24 Suppl):Abstr. S4–5. Denkert C et al. Ki67 Levels in Pretherapeutic Core Biopsies as Predictive and Prognostic Parameters in the Neoadjuvant GeparTrio Trial. Cancer Res. 2012;72(24 Suppl):Abstr. S4–5.
25.
Zurück zum Zitat Shin HC et al. Breast-Conserving Surgery After Tumor Downstaging by Neoadjuvant Chemotherapy is Oncologically Safe for Stage III Breast Cancer Patients. Ann Surg Oncol. 2013 Mar 16. [Epub ahead of print] Shin HC et al. Breast-Conserving Surgery After Tumor Downstaging by Neoadjuvant Chemotherapy is Oncologically Safe for Stage III Breast Cancer Patients. Ann Surg Oncol. 2013 Mar 16. [Epub ahead of print]
26.
Zurück zum Zitat Marinovich ML et al. Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI. Breast. 2012;21(5):669–77.PubMedCrossRef Marinovich ML et al. Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI. Breast. 2012;21(5):669–77.PubMedCrossRef
27.
Zurück zum Zitat Hylton NM et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy—results from ACRIN 6657/I-SPY TRIAL. Radiology. 2012;263(3):663–72.PubMedCentralPubMedCrossRef Hylton NM et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy—results from ACRIN 6657/I-SPY TRIAL. Radiology. 2012;263(3):663–72.PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat Giuliano AE et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569–75.PubMedCrossRef Giuliano AE et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569–75.PubMedCrossRef
29.
Zurück zum Zitat Boughey JC et al. The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0–T4, N1–2) who receive neoadjuvant chemotherapy — results from the ACOSOG Z1071 trial. Cancer Res. 2012;72(24 Suppl):Abstr. S2–1. Boughey JC et al. The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0–T4, N1–2) who receive neoadjuvant chemotherapy — results from the ACOSOG Z1071 trial. Cancer Res. 2012;72(24 Suppl):Abstr. S2–1.
30.
Zurück zum Zitat Kuehn T et al. Sentinel Lymph Node Biopsy Before or After Neoadjuvant Chemotherapy - Final Results from the Prospective German, multiinstitutional SENTINA-Trial. Cancer Res. 2012;72(24 Suppl):Abstr. S2–2. Kuehn T et al. Sentinel Lymph Node Biopsy Before or After Neoadjuvant Chemotherapy - Final Results from the Prospective German, multiinstitutional SENTINA-Trial. Cancer Res. 2012;72(24 Suppl):Abstr. S2–2.
Metadaten
Titel
Neoadjuvante Therapieoptionen
Operables Mammakarzinom
verfasst von
PD Dr Cornelia Liedtke
Prof. Dr. Achim Rody
Dr. Kristin Baumann
Publikationsdatum
01.04.2014
Verlag
Urban & Vogel
Erschienen in
gynäkologie + geburtshilfe / Ausgabe 2/2014
Print ISSN: 1439-3557
Elektronische ISSN: 2196-6435
DOI
https://doi.org/10.1007/s15013-014-0368-1

Weitere Artikel der Ausgabe 2/2014

gynäkologie + geburtshilfe 2/2014 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.